Ligand Pharmaceuticals, Inc.

Industry

  • Biotechnology
    • Transgenics
    • Large Molecule
      • Antibodies
    • Drug Discovery Technologies
  • Pharmaceuticals
    • Drug Delivery
      • Site Specific
    • Vaccines

Other Names/Subsidiaries

  • Ab Initio Biotherapeutics
  • Apeiron Biologics
  • Cita NeuroPharmaceuticals
  • Crystal Bioscience
  • CyDex Pharmaceuticals
  • Icagen Pharmaceuticals
  • Metabasis Therapeutics
  • Neurogen
  • Novan
  • Open Monoclonal Technology
  • Pelthos Therapeutics
  • Pelthos Therapeutics
  • Pfenex
  • Pharmacopeia
  • Taurus Biosciences
  • Vernalis
  • Verrow Pharmaceuticals
  • xCella Biosciences
See more in Biomedtracker

Latest on Ligand Pharmaceuticals, Inc.

Pink Sheet

Agenus Needs Phase III For BOT/BAL, Another Example Of Shifting Accelerated Approval Climate

 
• By Alaric DeArment

Agenus Inc. got an unwelcome surprise from the US Food and Drug Administration, which recommended against the company filing for accelerated approval for the combination of its CTLA-4-targeting monoc

Pink Sheet

Rare Diseases Rule, But Some Common Conditions Stand Out In Pending US Applications

 
• By Bridget Silverman

Rare diseases are almost certain to remain one of the biggest areas for novel drug development in 2024, but the orphan drug pipeline will be making space for some novel therapies for common conditions

Scrip

FDA Leaves Door Open For Further Discussions With Agenus Over BOT/BAL

 
• By Alaric DeArment

Agenus Inc. got an unwelcome surprise from the US Food and Drug Administration as the agency recommended against the company filing for accelerated approval for the combination of its CTLA-4-targetin

Scrip

Ligand Makes Second Big Oncology Investment In 2024 With Apeiron Buyout

 
• By Alaric DeArment

Ligand Pharmaceuticals, Inc. has made its second major oncology investment in two months with the acquisition of Apeiron Biologics AG and the Austrian biotech’s royalty rights for Qarziba (dinutuxi